Crizotinib is the first-generation ALK/MET/ROS1 tyrosine kinase inhibitor that established targeted therapy in ALK-rearranged and ROS1-positive non-small cell lung cancer. Simson Pharma's Crizotinib reference standard and impurities support stability-indicating method development for this foundational oncology agent.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Crizotinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.